Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Betamethasone valerate
Accord-UK Ltd
D07AC01
Betamethasone valerate
250microgram/1gram
Cutaneous cream
Cutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: 13040000; GTIN: 5060032242842
PATIENT INFORMATION LEAFLET AUDAVATE™ RD 0.025% W/W CREAM (BETAMETHASONE VALERATE) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What is Audavate RD and what is it used for 2. What you need to know before you use Audavate RD 3. How to use Audavate RD 4. Possible side effects 5. How to store Audavate RD 6. Contents of the pack and other information continued on the other side BBBA5610 1. WHAT IS AUDAVATE RD AND WHAT IS IT USED FOR Audavate RD contains a medicine called betamethasone valerate. It belongs to a group of medicines called steroids. It helps to reduce swelling and irritation. Audavate RD is used to help reduce the redness and itchiness of certain skin problems. These skin problems include eczema, psoriasis and dermatitis. RD stands for ‘Ready Diluted’. It contains less active ingredient than Audavate 0.1% preparations. It is used: • For milder skin problems, or • To keep your skin problem under control after Audavate 0.1% has improved it. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE AUDAVATE RD DO NOT USE AUDAVATE RD: • if you are allergic to betamethasone valerate or any of the other ingredients of this medicine (listed in Section 6) • on a child under 1 year old • to treat any of the following skin problems, it could make them worse: • acne • severe flushing of skin on and around your nose (rosacea) • spotty red rash around your mouth (perioral dermatitis) • circular to oval red plaques found over the body and the scalp (plaque psoriasis) • itching around yo Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Audavate RD 0.025% w/w Cream 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of cream contains 0.25 mg of betamethasone (0.025% w/w) as valerate. Also contains 72 mg of cetostearyl alcohol and 1 mg of chlorocresol. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cream White to almost white cream. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Betamethasone valerate ready diluted (Audavate RD) preparations are indicated for maintenance treatment once an acute episode has been treated effectively with a continuous course of betamethasone valerate (Audavate). Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following: Atopic dermatitis (including infantile atopic dermatitis) Nummular dermatitis (discoid eczema) Prurigo nodularis Psoriasis (excluding widespread plaque psoriasis) Lichen simplex chronicus (neurodermatitis) and lichen planus Seborrhoeic dermatitis Irritant or allergic contact dermatitis Discoid lupus erythematosus Adjunct to systemic steroid therapy in generalised erythroderma Insect bite reactions. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Creams are especially appropriate for moist or weeping surfaces. Once an acute episode has been treated effectively with a continuous course of betamethasone valerate, improvement may be maintained with a small amount of ready diluted betamethasone valerate applied once or twice a day. This regimen should be combined with routine daily use of emollients. The condition and the benefits and risks of continued treatment must be re-evaluated on a regular basis. _Paediatric population_ Betamethasone valerate is contraindicated in children under one year of age. Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter cou Read the complete document